Accelerated stability testing (study) Important Questions

Interview questions regarding accelerated stability testing/studies are explained following the ICH (Q1A, R2, and Q1B step 5) and FDA guidance. Conducting stability studies is important to ensure the quality, safety, and efficacy of drug products throughout their lifecycle, which is a prerequisite for accepting and approving any pharmaceutical product. These accelerated stability studies must be carried out systematically. Now, let’s delve into some important questions.

Accelerated stability testing (study) Important Questions

Question: What is Stability?

Ans: Stability refers to the capacity of a drug product to remain within its physical, chemical, therapeutic, and microbiological specifications during its entire shelf life. It includes factors such as temperature, humidity, light exposure, and packaging materials.

Question: Why accelerated stability testing is essential?

Ans: It is essential to continuously monitor the products for chemical degradation over time, leading to a reduced concentration of active drugs in the dosage form. Toxic substances may form during the degradation of active pharmaceutical drugs.

Question: Why are stability studies important in the pharmaceutical industry?

Ans: Stability studies are essential for ensuring the safety, efficacy, and quality of a drug product. They help in determining the appropriate storage conditions and shelf life of a drug to maintain its potency until it reaches the patient.

Question: What are the different types of stability studies?

Ans: There are three main types of stability studies:

  • Long-term stability studies
  • Accelerated stability studies
  • Intermediate or ongoing stability studies

Long-term stability studies, also known as real-time stability studies, involve storing a drug product under recommended storage conditions for its entire shelf life. Accelerated stability studies are conducted at higher temperatures and humidity levels to simulate the effects of prolonged storage in a short period.

Intermediate or ongoing stability studies are performed periodically throughout a drug’s shelf life to monitor its stability over time.

Question: What is the difference between shelf life and expiration date?

Ans: Shelf life refers to the recommended time period during which a drug product can maintain its quality, potency, and safety under specified storage conditions. The expiration date is the last day that a drug product is expected to remain within its approved specifications. It is determined based on stability studies and is typically shorter than the shelf life.

Question: What is the difference between real-time and accelerated stability studies?

Ans: Real-time stability studies involve storing a drug product at recommended storage conditions over its entire shelf life, while accelerated stability studies are conducted at higher temperatures and humidity levels to simulate the effects of prolonged storage in a short period.

Question: What are some common factors that can affect the stability of a drug product?

Ans: Some common factors that can affect the stability of a drug product include:

  • Temperature and humidity
  • Light exposure
  • Packaging materials
  • Chemical interactions between ingredients
  • Presence of impurities or degradation products

Question: How are stability studies conducted?

Ans: Stability studies are typically conducted according to guidelines set by regulatory bodies such as the International Council for Harmonisation (ICH). They involve testing samples of a drug product at predetermined time intervals and analyzing them for changes in physical, chemical, and microbiological properties.

Question: What is the difference between forced degradation studies and stability studies?

Ans: Forced degradation studies involve subjecting a drug product to severe conditions such as high temperature, humidity, or light exposure to accelerate its degradation. These studies are conducted to identify potential degradation products and determine their impact on the drug’s stability. Stability studies, on the other hand, involve storing a drug product under recommended conditions to determine its shelf life and storage requirements.

Question: How do you determine the appropriate storage conditions for a drug product?

Ans: The appropriate storage conditions for a drug product can be determined by conducting stability studies at different temperatures and humidity levels. The results of these studies help identify the optimal storage conditions that can maintain the drug’s stability and potency.

Question: How are stability data used in the development of a new drug product?

Ans: Stability data obtained from studies conducted during the development of a new drug product are required for determining its shelf life, packaging materials, and storage conditions. These data also help in establishing appropriate expiration dates and storage requirements for the final commercial product.

Question: Does significant change apply only to accelerated storage conditions or is it applicable to long-term study?

Ans: According to our ICH guidelines, significant changes apply to accelerated storage conditions when addressing this question. However, the product cannot be considered stable if significant changes occur in long-term storage conditions, and the organization cannot pursue approval from the regulatory agency.

ICH guidance specifies that if long-term studies are conducted at 25°C ± 2°C and 60% ± 5%, a significant change occurs during six months of testing at accelerated storage conditions. In such cases, additional testing at the intermediate storage condition should be conducted and evaluated against the criteria for significant changes.

The initial application should include a minimum of six months of data from a 12-month study at the intermediate storage condition. This pertains to the applicability of significant changes.

Question: How many API Lots are required to manufacture three batches of each strength of a proposed drug product?

Ans: According to ICH guidelines, there should be two API Lots to manufacture three batches of each strength of a proposed drug product.

Suppose the minimum of two Lots is not used to manufacture three batches of the drug product. FDA will consider it a significant deficiency and will refuse to receive the NDA application.

Question: Tell about various storage conditions for stability and time points.

Ans: 1. Short-term Accelerated stability: When testing under accelerated conditions, include time points at 0, 3, and 6 months. Additionally, cover one more time point. The specified storage conditions are 40°C ± 2°C at 75% ± 5% humidity.

2. Intermediate accelerated stability testing: In intermediate accelerated stability testing, time points occur at 0, 6, 9, and 12 months, and storage conditions are maintained at 30°C ± 2°C with 65% ± 5 RH.

3. long-term conditions: For Long-term conditions, time points occur at (0, 3, 6, 9, 12) during the first year, and every six months throughout the second year, such as (18, 24, 36 months). Storage conditions are 25°C ± 2°C at 60% ± 5%.

Question: If one out of the three batches stored under accelerated conditions shows a significant change, what should be done?

Ans: According to ICH guidance, if accelerated data shows a significant change or failure of any attribute in one or more batches, an applicant should submit intermediate data for all three batches. Additionally, the submission should include a failure analysis, which is a discussion concerning the observed failures.

If any significant change occurs between zero and six months, in that case, long-term data needs to be used for analysis. Six months of intermediate data are required at the time of an NDA submission, and a further 12 months of data are to be amended later on six months.

The evaluation at filing requires intermediate data, including zero and six months’ time points if the intermediate data fails. In such cases, extrapolation of shelf life or retest date is not allowed. The determination of shelf life or retesting depends only on long-term data, which will govern the sample storage requirements.

Question: How long should three pilot-scale batches be stored before destruction, as submitted as part of an NDA?

Ans: For the general NDA Submission batch, samples should be stored for one year after approval of the NDA, and samples of the drug product used for biocovalent studies must be stored for five years after approval of the NDA.

Note: Stay tuned here for more timely updates with added questions. Comment it needs for PDF Version.

Leave a Comment